Intellia Therapeutics, Inc. filings document the business, governance and capital structure of a Nasdaq-listed clinical-stage biopharmaceutical company developing CRISPR-based therapies. Its Form 8-K reports record quarterly financial results and business updates, clinical and regulatory disclosures for lonvo-z in hereditary angioedema, nex-z in ATTR amyloidosis, and related FDA communications.
The filing record also includes common stock financing disclosures, including an underwritten public offering and amendments to an at-the-market sales program. Proxy materials describe annual meeting matters, executive compensation, equity awards and board governance, while bylaw amendments and other corporate filings address shareholder proposal procedures, forum provisions and registered common stock listed on The Nasdaq Global Market.
Intellia Therapeutics, Inc. President and CEO John M. Leonard, who is also a director, reported a mandatory sell-to-cover stock transaction. On January 5, 2026, he sold 34,146 shares of common stock at $9.21 per share to cover tax withholding obligations arising from the vesting of restricted stock units on January 1, 2026. The filing states this was not a voluntary trade. After this transaction, Leonard beneficially owned 1,013,339 common shares directly and an additional 58,415 common shares indirectly held by the John M. Leonard 2015 Irrevocable Trust.
Intellia Therapeutics EVP and Chief Scientific Officer Birgit C. Schultes reported a mandatory tax-related stock sale. On January 5, 2026, she sold 8,508 shares of Intellia Therapeutics common stock at a price of $9.21 per share. A footnote explains this was a required “sell-to-cover” transaction to satisfy tax withholding obligations upon the vesting of restricted stock units on January 1, 2026, and not a voluntary trade. Following this transaction, she beneficially owned 98,533 shares of Intellia common stock, which include 925 and 932 shares acquired under the company’s 2016 Employee Stock Purchase Plan on June 30, 2025 and December 31, 2025, respectively.
Intellia Therapeutics executive James Basta reported a tax-related stock sale. On January 5, 2026, he sold 10,397 shares of Intellia Therapeutics common stock at a price of $9.21 per share. According to the filing, this was a mandatory “sell-to-cover” transaction to satisfy his tax withholding obligation from restricted stock units that vested on January 1, 2026, and it is explicitly described as not a voluntary trade. After this transaction, he beneficially owned 101,528 shares of Intellia common stock directly.
Intellia Therapeutics, Inc. director Fred E. Cohen reported an open market purchase of the company’s common stock. On January 5, 2026, he bought 150,000 shares of common stock at a weighted average price of $9.35 per share, coded as a purchase transaction.
According to the filing, these shares were acquired in multiple trades at prices ranging from $9.13 to $9.68. Following this transaction, Cohen beneficially owns 207,453 shares of Intellia Therapeutics common stock held directly.
Intellia Therapeutics EVP and Chief Medical Officer David Lebwohl reported a sale of common stock that was carried out solely to cover taxes on recently vested restricted stock units. On January 5, 2026, he sold 11,903 shares of Intellia Therapeutics common stock at $9.21 per share in a mandatory "sell-to-cover" transaction tied to RSUs that vested on January 1, 2026. After this transaction, Lebwohl beneficially owned 121,249 shares of Intellia common stock. This total includes 1,022 shares and 1,264 shares that were previously acquired through the company’s 2016 Employee Stock Purchase Plan on June 30, 2025 and December 31, 2025, respectively.
Intellia Therapeutics executive Eliana Clark reported an automatic share sale related to taxes. A Form 4 shows that on January 5, 2026, the EVP and Chief Technical Officer sold 9,515 shares of Intellia Therapeutics common stock at $9.21 per share. The filing explains this was a mandatory “sell-to-cover” transaction to satisfy her tax withholding obligation upon the vesting of restricted stock units on January 1, 2026, and does not represent a volitional trade by the reporting person.
After this transaction, she beneficially owns 87,118 shares of Intellia common stock, including 1,264 shares acquired under the company’s 2016 Employee Stock Purchase Plan on December 31, 2025.
Intellia Therapeutics EVP and CFO Edward J. Dulac III reported an automatic sale of company stock. On January 5, 2026, he sold 6,379 shares of Intellia Therapeutics common stock at a price of $9.21 per share. According to the disclosure, this was a mandatory “sell-to-cover” transaction to satisfy tax withholding obligations tied to restricted stock units that vested on January 1, 2026, and it is described as not being a voluntary trade by the executive. After this transaction, he beneficially owns 99,683 shares of Intellia Therapeutics common stock directly.
Intellia Therapeutics VP and Chief Accounting Officer Michael P. Dube reported a small insider stock sale linked to tax withholding. On January 5, 2026, he sold 2,989 shares of Intellia common stock at $9.21 per share, leaving him with 52,277 shares held directly after the transaction.
According to the footnote, this was a mandatory “sell-to-cover” transaction carried out to satisfy his tax withholding obligations arising from the vesting of restricted stock units (RSUs) on January 1, 2026. The disclosure states that this sale does not represent a voluntary trading decision by the reporting officer but an automatic sale tied to equity award taxation.
Intellia Therapeutics' President and CEO, who is also a director, reported stock option exercises and related share sales in company stock. On 12/11/2025, the reporting person exercised options to acquire 49,959 shares of common stock at an exercise price of $ 6.83 and sold 49,959, 32,832 and 5,355 shares in separate transactions with weighted average prices of $ 9.49, $ 9.47 and $ 9.59, respectively.
On 12/12/2025, additional options for 8,557 shares were exercised at $ 6.83. These option awards were granted under the company’s 2015 Stock Option and Incentive Plan and had vested in full as of 12/11/2025. The filing notes that the sales occurred automatically under a Rule 10b5‑1 trading plan adopted on 09/11/2025. Following these transactions, the reporting person beneficially owns 1,047,485 shares directly and 58,415 shares indirectly through the John M. Leonard 2015 Irrevocable Trust.
Intellia Therapeutics (NTLA) reported new clinical updates across two in vivo CRISPR programs. For hereditary angioedema, a pooled Phase 1/2 analysis of 32 patients receiving a one-time 50 mg dose of lonvoguran ziclumeran (lonvo-z) showed a mean 89% reduction in plasma kallikrein at month 24. 31 of 32 patients (97%) were attack-free and off long-term prophylaxis as of the August 29, 2025 cut-off, with a safety profile described as well tolerated up to three years of follow-up. The global Phase 3 HAELO trial completed enrollment in September 2025, with topline data expected by mid-2026.
For transthyretin amyloidosis with cardiomyopathy, the Phase 1 trial of nexiguran ziclumeran (nex-z) enrolled 36 patients and showed sustained serum TTR reduction; among nine patients at 36 months, the mean reduction was 87%. At 24 months, stability or improvement was seen in 70% (NT-proBNP), 85% (hs‑Troponin T), and 69% (6MWT), with 81% stable or improved NYHA class. A matched-cohort mortality analysis reported HR 0.27 (p=0.009). The FDA placed a clinical hold on the Phase 3 MAGNITUDE and MAGNITUDE‑2 trials on October 29, 2025.